Indonesia's $3.28 Billion MedTech Import Market Reset: The IVD Bubble Is Over; The Surgical Boom Has Begun

JERSEY CITY, N.J., Nov. 7, 2025 /PRNewswire/ -- Indonesia's medical technology (MedTech) import market underwent a profound transformation between 2021 and 2024, with total imports surging to a new high of $3.28 billion in 2024. This is according to a new report from Pure Global, "Indonesia's Medical Device and IVD Import Market: A Data-Driven Analysis (2021-2024)."

The study highlights a period of intense volatility and structural change, moving from a market defined by the pandemic to one driven by a long-term modernization agenda.

Based on historical data, the market's transformation occurred in three distinct phases:

1. 2021 Pandemic Peak ($2.24 Billion): Demand was high, driven by pandemic-specific needs.
2. 2022 Contraction (-19.9%): The market fell to $1.79 billion as post-pandemic normalization set in. Demand for pandemic-related items collapsed, with "Clinical Chemistry" (IVD/testing) plummeting by -72.6% and "Anesthesiology" (including ventilators) falling by -49.9%.
3. 2024 Unprecedented Rebound (+77.8%): Following stabilization in 2023 ($1.85 billion), the market surged to $3.28 billion in 2024.

The report emphasizes that the 2024 boom was not a simple recovery but a fundamental shift in market demand.

The growth was overwhelmingly powered by specialties related to elective and high-acuity procedures, reflecting a move to clear surgical backlogs and a long-term government strategy to improve domestic hospital capabilities.

2024 High-Growth Segments:

• Orthopedic: +552.8%
  
  
• Dental: +186.4%
  
  
• General & Plastic Surgery: +102.9%

The "General & Plastic Surgery" segment is now the market's largest by far, valued at $1.36 billion.

Shifting Competitive Dynamics

This structural change has significantly altered the competitive landscape for international suppliers:

• Greater China: Remains the largest supplier ($807.4 million), but its market share eroded from 33.3% in 2021 to 24.6% in 2024.
  
  
• United States: Emerged as a primary beneficiary. Grew +118.4% in 2024, boosting market share to 16.0%. Success was driven by aligning with high-growth Orthopedics (+902%) and General & Plastic Surgery (+182%) exports.
  
  
• Republic of Korea: Experienced the most volatility. Its market share dropped from 13.9% to 4.3% as its $231.1M Clinical Chemistry segment collapsed (-94.6%). It is now pivoting to new segments like Dental (+455%) and Orthopedics (+210%).
  
  
• Germany & Japan: Germany ($368.9 million) remains a stable, high-quality supplier, while Japan ($171.2 million) showed strong, consistent growth of +79.3%.

Questions This Report Answers

1. How did Indonesia's MedTech import market perform from 2021 to 2024?
   Answer: The market was highly volatile. It contracted by -19.9% in 2022 to $1.79 billion, then rebounded massively with +77.8% growth in 2024 to a new peak of $3.28 billion.
   
   
2. What caused the 2022 market contraction?
   Answer: The end of pandemic-era emergency procurement. The "Clinical Chemistry" (IVD/testing) segment collapsed by -72.6%, and "Anesthesiology" (respiratory support) fell by -49.9%.
   
   
3. What were the fastest-growing medical specialties in the 2024 rebound?
   Answer: The boom was driven by elective and surgical procedures. Top-growing specialties included Orthopedics (+552.8%), Ear, Nose, & Throat (+267.4%), and Dental (+186.4%).
   
   
4. Which country was the biggest winner from the 2024 market shift?
   Answer: The United States. Imports from the U.S. grew +118.4% (the fastest among the top 5), capturing 16.0% market share. This was driven by a +902% surge in Orthopedic exports and a +182% rise in General & Plastic Surgery exports.
   
   
5. What is the primary long-term driver for MedTech demand in Indonesia?
   Answer: The Indonesian government's Health System Transformation Agenda (HSTA). This national strategy aims to modernize hospitals and curb the $10.6 billion Indonesians spend annually on medical tourism.

Interesting Facts From the Report

1. The Rise of New Hubs: Beyond traditional leaders, 2024 saw new supply hubs emerge. Imports from Mexico surged +468.4% and Ireland +185.8%, pushing both into the top 10.
   
   
2. The Korean IVD Collapse: South Korea's reliance on pandemic testing was exposed as its Clinical Chemistry exports fell from $231.1M in 2021 to $12.4M in 2024, a -94.6% drop in its main segment.
   
   
3. A Market Transformed: The 2024 boom signaled a structural shift. The 2021 leader, "Clinical Chemistry" ($761.4M), shrank by over 70%, replaced by "General & Plastic Surgery" ($1.36B) and "Radiology" ($559.9M) as dominant segments.

Download the FULL copy of this research report directly from Pure Global.  

About Pure Global

Pure Global is the world's leading MedTech service provider for local representation and registration services, operating at the intersection of regulatory technology (RegTech), artificial intelligence (AI), and market intelligence. We streamline global access through representation and registration in over 30 markets, but our value extends to strategic growth. Every client benefit from exclusive market research reports, developed by ex-Wall Street analysts, that deliver actionable insights into the latest industry trends. This unique combination of regulatory and market expertise gives our clients an unparalleled advantage to succeed and lead in the MedTech space.

Contact

Pure Global
DJ Fang, Head of Global Market Research
[email protected]
For U.S.A. / Canada Call +1-888-768-1688

SOURCE Pure Global